title: Longitudinal Trend in Lipid Profile of Incident Peritoneal Dialysis Patients is Not Influenced by the Use of Biocompatible Solutions.
abstract: ♦
  
  
  BACKGROUND
  The longitudinal trends of lipid parameters and the impact of biocompatible peritoneal dialysis (PD) solutions on these levels remain to be fully defined. The present study aimed to a) evaluate the influence of neutral pH, low glucose degradation product (GDP) PD solutions on serum lipid parameters, and b) explore the capacity of lipid parameters (total cholesterol [TC], triglyceride [TG], high density lipoprotein [HDL], TC/HDL, low density lipoprotein [LDL], very low density lipoprotein [VLDL]) to predict cardiovascular events (CVE) and mortality in PD patients. ♦
  
  
  METHODS
  The study included 175 incident participants from the balANZ trial with at least 1 stored serum sample. A composite CVE score was used as a primary clinical outcome measure. Multilevel linear regression and Poisson regression models were fitted to describe the trend of lipid parameters over time and its ability to predict composite CVE, respectively. ♦
  
  
  RESULTS
  Small but statistically significant increases in serum TG (coefficient 0.006, p < 0.001), TC/HDL (coefficient 0.004, p = 0.001), and VLDL cholesterol (coefficient 0.005, p = 0.001) levels and a decrease in the serum HDL cholesterol levels (coefficient -0.004, p = 0.009) were observed with longer time on PD, whilst the type of PD solution (biocompatible vs standard) received had no significant effect on these levels. Peritoneal dialysis glucose exposure was significantly associated with trends in TG, TC/HDL, HDL and VLDL levels. Baseline lipid parameter levels were not predictive of composite CVEs or all-cause mortality. ♦
  
  
  CONCLUSIONS
  Serum TG, TC/HDL, and VLDL levels increased and the serum HDL levels decreased with increasing PD duration. None of the lipid parameters were significantly modified by biocompatible PD solution use over the time period studied or predictive of composite CVE or mortality.
authors.affiliation: Department of Renal Medicine, Princess Alexandra Hospital, Brisbane, Australia School of Medicine, University of Queensland, Brisbane, Australia Translational Research Institute, Brisbane, Australia.
authors.forename: Yeoungjee
authors.initials: Y
authors.lastname: Cho
authors.affiliation: Fresenius Medical Care Deutschland, Bad Homburg, Germany.
authors.forename: Janine
authors.initials: J
authors.lastname: Büchel
authors.affiliation: Fresenius Medical Care Deutschland, Bad Homburg, Germany.
authors.forename: Sonja
authors.initials: S
authors.lastname: Steppan
authors.affiliation: Department of Nephrology, University Clinic, Duesseldorf, Germany.
authors.forename: Jutta
authors.initials: J
authors.lastname: Passlick-Deetjen
authors.affiliation: Department of Renal Medicine, Princess Alexandra Hospital, Brisbane, Australia School of Medicine, University of Queensland, Brisbane, Australia Translational Research Institute, Brisbane, Australia.
authors.forename: Carmel M
authors.initials: CM
authors.lastname: Hawley
authors.affiliation: School of Medicine, University of Queensland, Brisbane, Australia Department of Chemical Pathology, Pathology Queensland, Princess Alexandra Hospital, Brisbane, Australia.
authors.forename: Goce
authors.initials: G
authors.lastname: Dimeski
authors.affiliation: Fresenius Medical Care, Sydney, Australia.
authors.forename: Margaret
authors.initials: M
authors.lastname: Clarke
authors.affiliation: Department of Renal Medicine, Princess Alexandra Hospital, Brisbane, Australia School of Medicine, University of Queensland, Brisbane, Australia Translational Research Institute, Brisbane, Australia david.johnson2@health.qld.gov.au.
authors.forename: David W
authors.initials: DW
authors.lastname: Johnson
mesh_terms: D000368:Aged; D001672:Biocompatible Materials / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control; D015314:Dialysis Solutions / Q000627:therapeutic use*; D005260:Female; D005947:Glucose / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008055:Lipids / Q000097:blood*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis; D012044:Regression Analysis; D051436:Renal Insufficiency, Chronic / Q000628:therapy*
chemical_list: D001672:Biocompatible Materials; D015314:Dialysis Solutions; D008055:Lipids; D005947:Glucose
keywords: Biocompatible; cardiovascular events; glucose degradation products; lipid; mortality; peritoneal dialysis